Please login to the form below

Not currently logged in
Email:
Password:

LionsDen Communications Award for Excellence in Payer and Policymaker Engagement

Sponsored by

Finalist

Osteosarcoma – rewriting the rule book

Takeda UK in association with Liberation Communications


Summary of work

Mepact (mifamurtide) is the first advance in osteosarcoma treatment for more than 20 years. A very rare form of bone cancer, osteosarcoma is highly aggressive with a propensity to metastasise, affecting around 150 children and young adults each year across the UK.

Before Mepact a third of all children and young adults diagnosed with osteosarcoma did not survive. With Mepact up to an estimated additional 12 children each year across the UK will survive osteosarcoma and go on to live “normal‟ long lives. 

In July 2010, NICE gave initial guidance, which did not recommend Mepact for use on the NHS in England despite a Patient Access Scheme (PAS) being proposed by Takeda. The SMC also gave a negative decision. 

Takeda worked with the Department of Health, NICE and the SMC to find a solution. After three further appraisal committee meetings, NICE acknowledged that to evaluate the health economic value of Mepact accurately, it would need to change its methodology to assess medicines, which improve survival rates beyond 30 years. 

Following a fifth appraisal committee meeting a positive decision for the use of Mepact was given. The SMC also reversed its initial negative decision to recommend the use of Mepact in Scotland.

 

 

Executive summary as submitted


COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Planning your clinical trial? Why you need to engage patients sooner
It’s highly likely that clinical studies are deterring patients based on decisions made in the early stages, such as during planning and design....
Patient-centricity in improving patient recruitment advertising
This blog looks into the importance of concepts and patient centricity in patient recruitment....
AI and life sciences
AI: the smart money is on the smart thinking
Looking at the three key areas where AI is being applied: drug discovery, clinical decision-making and clinical trials...

Infographics